Acute Refractory Heart Failure Related to SARS-CoV 2, ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2
Conditions
Keywords
ECMO, COVID-19, SARS-CoV2, ARDS, Myocarditis, Heart failure
Brief summary
The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to report the results of the ECMO management of the most severe forms of COVID-19 through the first French ECMO registry.
Detailed description
The main objective of this study is to evaluate the hospital survival of COVID-19 patients supported by venovenous or venoarterial ECMO in a multicenter registry. The secondary objectives are to describe the characteristics of COVID-19 patients who have received ECMO support, to identify the risk factors associated with hospital mortality, to analyze the outcomes after ECMO weaning including survival at day 28 and day 90, and to analyze the utility of a circulatory support mobile unit in a severe pandemic Inclusions are both prospective and retrospective in order to collect data over the whole pandemic
Interventions
None listed
Sponsors
Rennes University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* All COVID-19 patients, adults or children, * Tested positive by RT-PCR for SARS-CoV2 (nasopharyngeal swabs, sputum, endotracheal aspiration, bronchoalveolar lavage or stool sample) and / or with a diagnosis made on chest CT findings, * Supported by venovenous or venoarterial ECMO
Exclusion criteria
* Temporary legally protected Adults over a set period or waiting for protection supervision, guardianship * Patients or proxies who express their opposition to study participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hospital mortality | up to 90 days | Hospital mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality Day 28 | Day 28 | Mortality Day 28 |
| Mortality Day 90 | Day 90 | Mortality Day 90 |
| Ventilator-free days | Day 28 | Ventilator-free days |
| Intensive care unit-free days | Day 28 | ICU-free days |
| Hospital-free days | Day 28 | Hospital-free days |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORNicolas Nesseler, doctor
Rennes University Hospital
PRINCIPAL_INVESTIGATORAndré Vincentelli, professor
University Hospital, Lille
Outcome results
None listed